Neuroscience

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

New DDW Highlights episode: 15 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

This week in drug discovery (7-11 Oct) 

News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More

#News

Neurons
#Bipolar #Neuroscience #Psychiatry #Society for Neuroscience #Walsh Research Institute

Breakthroughs in bipolar disorder announced at Neuroscience 2024

A Walsh Research Institute scientist presented an advanced theory of bipolar disorder at the annual meeting of the Society for Neuroscience, Neuroscience 2024. After a multi-year investigation of recent neuroscience advances, Dr William Walsh believes he has resolved many unknowns that have puzzled researchers for a… Read More

#News #Trending News

Pluripotent stem cells
#Cell therapy #Neuroscience #Pluripotent stem cells #Society for Neuroscience #Stem cells

Neuroscience 2024: Leveraging human stem cells to treat diseases

Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases. Several interwoven examples have been discussed at Neuroscience 2024, the annual meeting of the Society for Neuroscience. Over 40% of the global population lives with some… Read More

#News #Trending News

Ozempic Insulin injection pen
#Diabetes #GLP-1 #Neuroscience #Obesity #Society for Neuroscience #Weight loss

News from SfN’s Neuroscience 2024: The brain on GLP-1 agonists

Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024 uncovering potential novel therapeutic benefits and behavioural side effects. About one in eight adults… Read More

#News #Trending News

Neurons in the brain
#Events #Lab technology #Neuroscience #Webinar

DDW Neuroscience Showcase presentation announcement

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures will outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase will include… Read More

#News

Neurons
#Ageing #CRISPR #Gene editing #Neuroscience #Regenerative Medicine #Stanford University

CRISPR gene editing reduces brain function decline with age

A new study has revealed that reducing the activity of a particular gene using CRISPR gene editing can rejuvenate stem cells in the brain to create fresh neurons. The finding in mice could open new avenues for potential therapeutics to improve brain function and reduce regenerative… Read More

#Editor's Choice #News

#Cystic fibrosis #Financing #Funding #Neuroscience #Oncology #Rare disease

This week in drug discovery (30 Sept – 4 Oct) 

News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer. The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in… Read More

#News

Neuronal inclusions in Huntington’s disease
#Financing #Huntington's disease #LoQus23 Therapeutics #Neurodegenerative disorders

New therapy for Huntington’s disease gets £35 million boost

Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing. The financing round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion General Partner Rogier Rooswinkel will join LoQus23’s Board of Directors. LoQus23 was founded… Read More

#Business & Investment #News

Neuroscience Parkinson's disease
#Mitsubishi Tanabe Pharma America #Neurodegenerative disorders #NeuroDerm #Parkinson's #Phase III trial

Data support one-year efficacy of ND0612 in Parkinson’s disease

New data from the Phase III BouNDless trial and its ongoing open-label extension (OLE) support the long-term efficacy of ND0612 in people with Parkinson’s disease (PD) experiencing motor fluctuations. The new clinical trial data was shared at the 2024 International Congress of Parkinson’s Disease and Movement… Read More

#News

#Events #Neuroscience #Society for Neuroscience

Looking forward to SfN’s Neuroscience 2024

Ahead of the Society for Neuroscience's (SfN) Neuroscience 2024 in Chicago, US from 5-9 October, DDW’s Megan Thomas, speaks to SfN President Dr Marina Picciotto, and looks at what we can expect from this annual global neuroscience event.  SfN perspective Dr Marina Picciotto reflects that the SfN annual meeting started… Read More

#Exclusive Content

#Drug development #Drug discovery #Drug technology #Neuroscience #Webinar

Watch DDW’s first Neuroscience Showcase

In this free online event at 3pm BST on 24 October, hosted by DDW and sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel… Read More

Webinar date:
Co-sponsored by ApconiX and AxoSim
#News

Neuroscience innovation
#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Last chance: Driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Brain inflammation
#Bristol Myers Squibb #FDA #Neuroscience #PureTech #Schizophrenia

New approach to schizophrenia treatment secures US approval

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. “Schizophrenia… Read More

#News #Regulatory #Trending News

Microbiome
#Drug development #Drug discovery #Mental health #Microbiome #Oncology

Hot off the press: Read the Fall issue of DDW now

The DDW Fall issue is out now and asks if the gut microbiome can unlock new therapeutics for mental health disorders, places a spotlight on oncology and includes a market report on the North American drug discovery hotspots. It also features an exclusive guide on… Read More

#Editor's Choice #News